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Abstract
Background: The HIV-1 accessory protein known as viral infectivity factor or Vif binds to the host
defence factor human APOBEC3G (hA3G) and prevents its assembly with viral particles and
mediates its elimination through ubiquitination and degradation by the proteosomal pathway. In the
absence of Vif, hA3G becomes incorporated within viral particles. During the post entry phase of
infection, hA3G attenuates viral replication by binding to the viral RNA genome and deaminating
deoxycytidines to form deoxyuridines within single stranded DNA regions of the replicated viral
genome. Vif dimerization has been reported to be essential for viral infectivity but the mechanistic
requirement for Vif multimerization is unknown.
Results:  We demonstrate that a peptide antagonist of Vif dimerization fused to the cell
transduction domain of HIV TAT suppresses live HIV-1 infectivity. We show rapid cellular uptake
of the peptide and cytoplasmic distribution. Robust suppression of viral infectivity was dependent
on the expression of Vif and hA3G. Disruption of Vif multimerization resulted in the production of
virions with markedly increased hA3G content and reduced infectivity.
Conclusion: The role of Vif multimerization in viral infectivity of nonpermissive cells has been
validated with an antagonist of Vif dimerization. An important part of the mechanism for this
antiretroviral effect is that blocking Vif dimerization enables hA3G incorporation within virions.
We propose that Vif multimers are required to interact with hA3G to exclude it from viral particles
during their assembly. Blocking Vif dimerization is an effective means of sustaining hA3G
antiretroviral activity in HIV-1 infected cells. Vif dimerization is therefore a validated target for
therapeutic HIV-1/AIDS drug development.
Background
HIV-1 viral infectivity factor (Vif) is an accessory protein
required for productive infection in nonpermissive cells
[1-3]. An important mechanism of Vif involves its ability
to bind to both Elongin B/C complex of the ubiquitina-
tion machinery and to the human host defence factor
APOBEC3G (hA3G). Formation of these complexes medi-
ates ubiquitination of hA3G and targets hA3G for destruc-
tion by the proteosome [4-11]. In the absence of Vif,
hA3G assembles within viral particles [6,12-18] and upon
post entry, attenuates viral replication through its interac-
tion with the viral RNA genome [12,19-21]. hA3G also
catalyzes dC to dU hypermutation during replication on
single stranded proviral DNA, resulting in templating of
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dG to dA mutations during replication of the coding
strand [15,22-28].
Vif homodimerization has been shown to be important
for HIV-1 infectivity and to involve amino acids
161PPLP164 [29,30]. Recent chemical cross-linking of Vif
in vitro suggested Vif forms dimers, trimers and tetramers
[31]. The multimerization domain is located C-terminal
to the putative SOCS box homology domain
(144SLQYLAL150), predicted to be required for Vif inter-
action with the Elongin B/C complex [7]. A3G binding
has been mapped to the N-terminal region of Vif
[4,10,32,33].
Mass spectrophotometric analysis of peptides released by
proteolysis of chemically cross-linked Vif suggested that
there were more intra- and intermolecular contacts
involving the N-terminal half of Vif compared to the C-
terminal half, suggesting that the N-terminus of Vif may
be more ordered [31]. The significance of these findings is
unclear in the absence of a crystal structure of Vif and Vif
multimers.
Two laboratories have predicted a structure of Vif through
computational methods involving comparative model-
ling of Vif relative to known structural folds in the Protein
Database [34,35]. Although the groups used different
clades of HIV-1 Vif for modelling, the amino acid
sequence immediately flanking and including the dimeri-
zation domain (KPPLPSV) and PPLP alone had a similar
predicted structure (root mean square deviation of 2.91 Å
and 2.49 Å, respectively; personal communication, David
H. Mathews). Both models predicted that the dimeriza-
tion domain lies on the surface of Vif monomers where it
would be exposed to solvent and accessible for interacting
with other Vif molecules or other proteins.
Using the putative Vif SOCS box and the known crystal
structures of other SOCS box proteins, the model of Lv et
al., also predicted the structure of the heterotrimeric com-
plex of Vif with Elongin B and C. In this model, Vif PPLP
remained solvent exposed. Modelling could not predict
the structure of Vif dimers and therefore the conformation
of PPLP in the interface of Vif dimers is unknown. This
underscores the importance of empirically determining
whether PPLP is accessible for therapeutic targeting in an
infected cell.
Peptide mimics of the dimerization domain have been
identified through selection of peptide sequences that
bind to Vif using phage display technology [29,30]. These
peptides disrupted Vif multimerization in vitro as evi-
denced by co-immunoprecipitation analysis of Vif with
different epitope tags. When the peptides were fused to
the antenipedia cell transduction sequence and added to
cell culture media, they markedly suppressed viral infec-
tivity in nonpermissive cells. These intriguing finds have
not been independently confirmed.
In this report two commercial laboratories (ImQuest Bio-
Sciences and OyaGen, Inc.) have confirmed that the pep-
tide sequence original identified by Yang et al. [29] has
anti-viral activity. We show that an eleven amino acid Vif
dimerization antagonist peptide derived from the
sequence originally reported by Yang et al., when fused to
the HIV TAT transduction peptide rapidly entered cells
and distributed within the cell cytoplasm. This peptide
suppressed live HIV-1 viral infectivity in a spreading infec-
tion assay. Targeting Vif dimerization resulted in a marked
increase in hA3G recovery in viral particles released from
cells within 24 hours post-infection and these particles
had reduced infectivity. The data demonstrate that Vif
dimerization plays an essential role in regulating hA3G
and validate the multimerization domain of Vif as a
potential drug target for anti-retroviral therapeutic devel-
opment.
Results and Discussion
Vif Dimerization Antagonist Peptide Suppresses HIV-1 
Infectivity
HIV-1 requires Vif for productive infectivity of T-lym-
phocytes, macrophages and dendritic cells expressing
hA3G [36-39]. In the absence of Vif, hA3G binds to Gag
and viral RNA to become incorporated into viral particles
[18,40-42]. The interaction of Vif with hA3G is broadly
considered to hold potential for the development of a
novel class of antiretroviral therapeutics [25,36,37,43,44].
The Vif dimerization antagonist peptide that was origi-
nally reported to suppress viral infectivity [29] consisted
of an N-terminal antenipedia homeodomain cell trans-
duction peptide (RQIKIWFQNRRMKWKK) fused to a
phage display-selected peptide (SNQGGSPLPRSV). We
replaced the insect transduction domain with the HIV TAT
transduction domain (YGRKKRRQRRRG) in the synthesis
of Peptide 1 (YGRKKRRQRRRGSNQGGSPLPRSV).
At ImQuest BioSciences, Peptide 1 was added (final con-
centration of 50 μM) every other day to the media of cul-
tures of the MT2 nonpermissive cell line that had been
infected with live HIV-1NL4-3 at moi. of 0.01 to determine
its efficacy as an antiviral agent in a spreading infection
assay. Viral replication was determined by assaying reverse
transcriptase activity in cell lysates. As a control for the
effect of cell transduction and the introduction of protein
into cells on viral infectivity, a segment of human serum
albumin (37DLGEQHFKGLVL48) with an N-terminal
TAT sequence was transduced into cells (control peptide).
Consistent with previous findings, Peptide 1 reduced viral
infectivity relative to the control peptide (Figure 1). ThisRetrovirology 2007, 4:81 http://www.retrovirology.com/content/4/1/81
Page 3 of 11
(page number not for citation purposes)
was particularly apparent within the first 9 days of infec-
tion and by the end of the study at 20 days. Peptide 1 was
not as effective as AZT (1 μM final concentration) in sup-
pressing viral infectivity. Suppression of viral infectivity by
Peptide 1 also was observed at higher moi (0.1) and in
spreading infections using H9 cells (data not shown).
Peptide 1 does not contain the native Vif amino acid
sequence of the dimerization domain (154KPKQIKPPLPR
SV167) and therefore we asked what is the minimal
sequence of Peptide 1 that would be necessary and suffi-
cient to reduce viral infectivity. Peptide 2 (YGRKKRR-
QRRRGQGGSPLPSRV) was the shortest peptide
synthesized that retained antiviral activity (peptide length
requirements determined with live virus in H9 cells
through contracted research in the laboratory of Dr. Hui
Zhang, Thomas Jefferson University). On a molar basis,
Peptide 2 had greater efficacy in suppressing HIV-1 infec-
tivity than Peptide 1 (Figure 1). Analysis of the dose
response of viral infectivity to Peptide 2 demonstrated an
apparent IC50 of 50 nM. However only an IC85 could be
achieved with a dose of 50 μM (Figure 2). Higher doses
were not tested. Peptide 2 therefore also is not as effective
in inhibiting HIV-1 infectivity as AZT (IC50 of 2–30 nM
and IC95 of 5 μM [45,46]).
Peptides with fewer amino acids on the N-terminus or C-
terminus of the phage display selected peptide sequence
had very low or no ability to suppress viral infectivity
(data not shown). All subsequent analyses were con-
ducted with Peptide 2 at 50 uM.
Validation of the Intracellular Target for Peptide 2
Vif is predominantly a cytoplasmic protein [47,48]. To
validate that Peptide 2 entered the cell and thereby had
access to Vif, it was synthesized with a C-terminal FITC tag
and added to the media of either MT2 or H9 cell cultures.
At OyaGen, Inc. cells were fixed at various times after Pep-
tide 2-FITC was added, then washed extensively with
phosphate buffered saline and stained with DAPI prior to
microscopy to visualize the nuclei of the cells. Fluores-
cence microscopy revealed an intracellular distribution of
Peptide 2-FITC within 5 minutes of its addition to the cell
culture media (Figure 3). There was no evidence for
plasma membrane accumulation. Peptide 2-FITC locali-
zation was predominantly cytoplasmic and remained so
Peptide 2 has an IC50 of 50 nM Figure 2
Peptide 2 has an IC50 of 50 nM. MT2 cells were treated 
by Imquest BioSciences with varying doses of Peptide 2 in a 
spreading infection and infectivity assayed as described in 
Methods. The percent inhibition of viral infectivity by the 
peptide was determined during the first seven days of the 
spreading infection assay. The Inhibitor Concentration, IC 
(indicated within each histogram) was calculated relative to 
the untreated virus control.
0
20
40
60
80
100
P
e
r
c
e
n
t
 
o
f
 
C
o
n
t
r
o
l
 
I
n
f
e
c
t
i
v
i
t
y
Doses
50
μM
5
μM
50
nM
5
nM
Vif Dimerization Antagonist Peptides Suppress HIV-1 Infec- tivity Figure 1
Vif Dimerization Antagonist Peptides Suppress HIV-
1 Infectivity. MT2 cells grown in microtiter dishes where 
infected with live HIV-1 virus at 0.01 and treated every other 
day with either AZT (1 μM), Control peptide (50 μM), Pep-
tide 1 (50 μM) or Peptide 2 (50 μM) or left untreated (viral 
control) as described in Methods. At the indicated days post-
infection, cells were harvested for cell lysate preparation and 
reverse transcriptase quantification as described in Methods. 
Lysates were prepared from parallel cultures of uninfected 
and untreated cells (cell control) as controls for the reverse 
transcriptase assays.
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Intracellular Distribution of Peptide 2 Figure 3
Intracellular Distribution of Peptide 2. H9 and MT2 cells were treated with 50 μM Peptide 2-FITC and after 5 minutes of 
incubation, the cells were fixed, mounted with DAPI-containing media and fluorescence microscopy was performed with filters 
for DAPI and FITC as described in Methods. Longer durations of treatment were also evaluated in a similar manner. The 
images were manually overlaid to superimpose the image of the nucleus with each image of Peptide 2-FITC distribution in the 
cell. Cells from two different regions of the H9 and MT2 plates are shown.Retrovirology 2007, 4:81 http://www.retrovirology.com/content/4/1/81
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for up to 24 hours, diminishing in fluorescence intensity
over time (t1/2 = 7 to 12 h).
The cytoplasmic localized peptide appeared both punc-
tate and diffuse (Figure 3), consistent with an initial pino-
cytotic uptake of the peptide followed by TAT-mediated
intracellular diffusion [49]. A similar distribution was
observed in both MT2 and H9 cells. Given that A3G is
restricted to the cytoplasm of cells [50], it is significant
that the distribution of Peptide 2 was predominantly cyto-
plasmic as this suggests that disruption of Vif dimeriza-
tion in the cytoplasm could have an effect on Vif
interaction with A3G.
Recent studies have suggested that the major role for Vif in
HIV-1 infectivity is to overcome the innate host defence of
hA3G [36,37,43,51]. We therefore asked whether the anti-
viral effect of Peptide 2 was dependent on the expression
of hA3G in the cells and viral Vif. HEK293T cells are per-
missive cells that do not naturally express hA3G however
transfection with hA3G in these cells makes them nonper-
missive to HIV-1 lacking Vif [15]. At OyaGen, Inc. pseudo-
typed HIV virions were produced in HEK293T cells by co-
transfecting with HIV-1 proviral DNA (or ΔVif virus that is
incapable of expressing Vif) and VSV-G with or without
co-transfection with hA3G cDNA. Cells were either treated
with PBS or Peptide 2.
Viral particles released into the cell culture supernatant
were harvested 24 h post transfection, normalized for p24
abundance and their infectivity quantified by lumines-
cence using a HeLa cell system (JC53-bl) containing an
LTR-driven luciferase reporter. Infectivity of +Vif virus pro-
duced under varying conditions is shown in the panel of
histograms on the left of Figure 4. The infectivity of +Vif
virus produced in the absence of hA3G and Peptide 2
(+Vif/-A3G/-peptide) was set to 100% for the purpose of
this comparison. As expected, in the absence of peptide,
the infectivity of +Vif virus produced in 293T cells express-
ing hA3G was not significantly different from the infectiv-
ity of +Vif virus in the absence of hA3G (left panel, first
and second histograms) due to the ability of Vif to sup-
press the antiviral activity of hA3G. However, treatment of
these producer cells with Peptide 2 significantly sup-
pressed the infectivity of +Vif virus (left panel, third and
fourth histograms, p ≤ 0.01, n = 3). Notably, the level of
suppression of viral infectivity by the peptide was signifi-
cantly greater (p ≤ 0.01, n = 3) when hA3G was expressed
(left panel, compare the third and fourth histograms).
While these data suggested a role for hA3G in the mecha-
nism leading to the most robust antiviral activity of Pep-
tide 2, it was surprising to find that the peptide also
reduced viral infectivity of +Vif virus produced in cells
lacking hA3G. This finding suggested that Vif multimeri-
zation supported viral infectivity through an hA3G-inde-
pendent mechanism. To rule out non-specific effects, we
evaluated whether peptide-treated cells had reduced via-
bility or proliferation. Trypan blue exclusion analysis sug-
gested that Peptide 2 only reduced cell viability by 6%
compared to untreated cells over a 48 h period of dosing
(data not shown). Cell cycle progression of untreated cells
and cells treated with peptide for 24 h was evaluated by
fluorescence activated cell sorting analysis of DNA con-
tent as described in Methods. The percent of the cell pop-
ulation in G1, S and G2/M phases of the cell cycle was
similar under both conditions (Figure 5). Therefore
reduced viral infectivity of the +Vif virus produced in pep-
tide-treated cells lacking hA3G cannot be explained by
off-target effects that altered cell viability or proliferation.
To demonstrate that Vif was required for the antiviral
activity of Peptide 2 we evaluated the effect of peptide on
ΔVif virus infectivity. The ΔVif produces fewer viral parti-
cles per ug of transfected plasmid than proviral DNA plas-
mids expressing Vif (see Figure 4 legend). Using p24
content to normalize virus input, the infectivity of ΔVif
virus produced in the absence of hA3G and without Pep-
tide 2 (ΔVif/-A3G/-peptide) was significantly reduced
compared to +Vif virus in the absence of hA3G (set as the
Robust Antiretroviral Activity of Peptide 2 Requires Expres- sion of Both Vif and A3G Figure 4
Robust Antiretroviral Activity of Peptide 2 Requires 
Expression of Both Vif and A3G. HEK293T cells were 
co-transfected with either VSV-G pseudotyped, + Vif (left 
panel) or ΔVif provirus (right panel), with or without A3G 
(as indicated below each histogram). During the incubation 
period, Peptide 2 was dosed into the specified samples (50 
μM final concentration). The viral particles collected from 
the cell culture media over 48 h were normalized for their 
p24 content and incubated with JC53-bl cells for analysis of 
infectivity corresponding to luminescence as described in 
Methods. Infectivity of +Vif virions is shown as percent of the 
infectivity measured for +Vif/-hA3G/-peptide condition 
(14,498 red units). The (-) A3G/ΔVif virus control virions 
lacked Vif and the cells did not express A3G. Infectivity of 
the ΔVif virions is shown as percent of the infectivity meas-
ured with ΔVif/-hA3G/-peptide conditions (5,827 red units). 
The error bars represent the standard deviation with n = 3.
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100% infectivity control). In the absence of hA3G, ΔVif
virion infectivity was not significantly affected by treating
the producer cells with Peptide 2 (Figure 4, right panel,
compare first and third histogram). As anticipated, hA3G
expression in producer cells had a devastating effect on
ΔVif viral infectivity, reducing viral infectivity to below
~10% (right panel, second histogram) of that seen with
the +Vif virus minus hA3G. Treatment of the producer
cells without hA3G with Peptide 2 appeared to further
decrease the infectivity ΔVif virus (right panel, compare
second and fourth histograms) however the difference in
infectivity of ΔVif virus produced in untreated and treated
cells is largely accounted for by the 6% reduced cell viabil-
ity of peptide-treated cells as described above. We cannot
rule out that the presence of Peptide 2 in these cells or pos-
sibly in the ΔVif viral particle may have had a deleterious
effect on viral particles assembly or post entry replication.
This is a possibility as the literature suggests that Vif itself
may be assembled and processed in viral particles [52].
We conclude from our study that the most significant sup-
pression of viral infectivity was observed when Vif and
hA3G were co-expressed and that the efficacy of Peptide 2
is dependent on the expression of Vif.
At the time when Vif dimerization was described, it was
not known that Vif prevented hA3G incorporation into
viral particles and that Vif promoted hA3G ubiquitination
and degradation and that [4-6,8-11,32,48,53]. We next
asked whether treatment of cells with Peptide 2 would
affect the recovery of hA3G with viral particles. OyaGen,
Inc. produced pseudotyped HIV-1 virus particles in 293T
cells co-transfected with hA3G cDNA with or without
treatment with Peptide 2. Viral particles were harvested
from cell culture media 24 h post-transfection and whole
cell extracts were prepared. A representative number of
cells (as whole cell extract) and a similar number of viri-
ons were resolved by SDS PAGE and western blotted from
two separate experiments.
Blots of whole cell extracts probed simultaneously with
antibodies reactive with β actin and hA3G revealed that
the expression of hA3G was similar in cells with or with-
out peptide treatment (Figure 6A, left panel). Blots of viral
particle proteins isolated from the cell culture superna-
tants were probed with antibody reactive with hA3G and
then reprobed with antibody reactive with p24 (as a
means of normalizing the recovery of hA3G with viral par-
ticles) (Figure 6A, right panel). These data demonstrated
that virions released from cells treated with Peptide 2 had
markedly greater recovery of hA3G relative to those
released from cells that were not treated with the peptide.
Analysis of the infectivity of p24-normalized virus dem-
onstrated that viral particles prepared from cells treated
with Peptide 2 had significantly (p < 0.01, n = 3) reduced
infectivity (Figure 6B).
Conclusion
We have addressed the therapeutic potential of the Vif
dimerization domain as an antiretroviral drug target by
providing the first independent confirmation that pep-
tides, previously characterized as Vif dimerization antago-
nists, suppress HIV-1 infectivity. We have used a peptide
mimetic of the Vif dimerization to confirm that the Vif
dimerization interface is accessible in infected cells as a
drug target and required for HIV-1 infectivity in nonper-
missive cells. Co-expression of Vif and hA3G were neces-
sary for a robust suppression of viral infectivity by the
peptide. A novel finding in this study is that peptides pre-
viously shown to disrupt Vif dimerization enabled more
hA3G to assemble with HIV-1 viral particles and
enhanced the ability of hA3G to function as a post-entry
host defence factor. The data explain why the most
marked antiviral effect of the peptide was observed when
Vif and hA3G were co-expressed. In fact, HIV-1 infectivity
is strongly correlated with Vif-dependent reduction of
hA3G assembly with viral particles [6,53]. The ability of
Peptide 2 to reduce hA3G abundance in the viral particle
without bringing about a reduction in total cellular hA3G
supports literature suggesting that Vif, and in the case of
our analysis, Vif multimers, may function to block hA3G
assembly with virions through a mechanism that is sepa-
rable from Vif-dependent hA3G degradation [51,54].
However, we hasten to add that hA3G was overexpressed
in our system and is therefore higher in abundance than
native expressed hA3G. Vif-dependent degradation of
Peptide 2 Does Not Affect Cell Cycle Progression Figure 5
Peptide 2 Does Not Affect Cell Cycle Progression. 
Cultures of HEK293T cells at a starting confluency of 30% 
were either untreated, treated with buffer alone or with 50 
μM Peptide 2 for 24 hours and processed for FACS analysis 
as described in Methods. The percent of cells in G1, S and 
G2/M phases of the cell cycle were calculated based on the 
DNA staining distributions.
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hA3G may not have been able to keep pace with the level
to which hA3G was being overexpressed. If this was
indeed the case, then it would leave open the possibility
that Vif-dependent hA3G degradation may have taken
place within a subcellular pool of hA3G that otherwise
would have been directed into viral particle assembly
pathway (such as newly translated hA3G). Peptide 2 act-
ing as a Vif dimerization antagonist may have selectively
affected the ability of Vif to block this pool of hA3G from
assembling with viral particles.
We have also observed that Peptide 2 induced a reduction
of +Vif virus infectivity in the absence of hA3G. This effect
was not caused by reduced cell viability and proliferation
due to peptide treatment. At face value the antiviral activ-
ity of the peptide in the absence of hA3G expression
would suggest that Vif multimerization facilitates viral
infectivity through a yet-to-be described mechanism. A
related conclusion has been draw from other studies that
found no evidence for overt changes in ΔVif virus viral
replication or packaging in hA3G expressing cells and
concluded that the defect in ΔVif virus replication was
likely due to other functions of Vif [1].
The current leading hypothesis is that the primary role for
Vif is to bind to hA3G and induced its degradation via the
proteosome [4-11]. In this way, Vif prevents hA3G from
being assembled with virions and acting as a post entry
block to viral replication [6,12-15,17-21]. A role for Vif in
viral infectivity other than to degraded hA3G is controver-
Virions Treated with Peptide 2 Contain More A3G and have Reduced Infectivity Figure 6
Virions Treated with Peptide 2 Contain More A3G and have Reduced Infectivity. (A) Virions collected from two 
separate experiments of HEK293T co-transfected with (+) Vif-provirus, VSV-G and A3G, with and without Peptide 2 treat-
ments (50 μM), were normalized for p24 and sedimented through a sucrose cushion as described in Methods. The resultant 
pellets were lysed and resolved via SDS-PAGE and western blotted for A3G and p24. P24 was re-probed in the western blot in 
addition to the p24 ELISA quantification to validate the normalization. (B) Virion samples harvested from the co-transfection 
were normalized for p24 and infected into JC53-bl cells to quantify infectivity by luminescence analysis as described in Methods. 
Bars represent standard deviations with an n = 3.
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sial. Examples of alterative functions for Vif include stabi-
lization of reverse transcription complexes [47,55,56],
efficient tRNALys/3 priming of reverse transcriptase com-
plexes [57] and facilitating viral particle assembly [58-60].
Moreover, interactions between Vif and cellular proteins
other than hA3G [61-63] and Vif phosphorylation by cel-
lular kinases [64] have been reported as part of the infec-
tion process.
We cannot rule out that disruption of Vif multimers (i.e.
the formation of Vif monomers) or the presence of Vif-
Peptide 2 complexes could have impaired viral and host
functions that otherwise would have supported viral
infectivity. Moreover another area of controversy is
whether Vif supports viral particle assembly and is pack-
aged with virions [52,55,56,58-60]. Further studies will be
necessary to determine whether Peptide 2 can be assem-
bled with virions and exert its effect by inducing defects in
viral particle assemble or post entry during viral replica-
tion.
In conclusion, the data present here suggested that dimers
or higher order multimers of Vif were required for the
interaction of Vif with hA3G and were an important part
of the mechanism where by HIV-1 overcomes hA3G as an
innate cellular defence factor. Validation of the Vif dimer-
ization domain as an accessible target therefore holds
promise for future therapeutic antiretroviral drug devel-
opment.
Methods
Peptide design and synthesis
All peptides used in this study were synthesized by Davos
Chemical Corp, Upper Saddle River, NJ or SigmaGenosys
St. Louis, MO with > 95% purity. Peptides 1 and 2 were
derived from sequence reported by Yang et al., from phage
display peptides that disrupted Vif dimerization and
blocked viral infectivity [29]. The control peptide was
selected from human albumin sequence (accession #
AAA98797) as a region of with no functional significance.
HIV Tat sequence (YGRKKRRQRRRG) was included at the
N-terminus of each peptide for cell transduction. For cell
uptake studies, Peptide 2 was synthesized with a C-termi-
nal FITC tag (Sigma Genosys). Cell cultures were dosed
with the indicated final concentration of peptides from a
750 μM stock solution of peptide prepared fresh in phos-
phate buffered saline. Cell viability was assessed by a
trypan blue exclusion assay preformed as described by the
vendor (Invitrogen).
Infectivity Assays and Quantification
Infectivity assays for Figure 1 were carried out as a fee for
service by ImQuest BioSciences (Frederick, MD). For these
studies MT-2 cells and the laboratory-adapted strain HIV-
1IIIB were obtained from the NIAID AIDS Research and
Reference Reagent Program, Rockville, Maryland. MT-2
cells were infected in 96-well microtiter plates at varying
moi and cell density of 5.0 × 103 cells/well in a total vol-
ume of 200 μL. Infectivity was monitored by RT activity in
each of the cultures at the indicated intervals. Peptides
were added to the cultures on day one of the infection and
every other day as the half-life of the peptide in media is
7–12 h (established by OyaGen, Inc., data not shown).
Viral replication was assessed at ImQuest BioSciences by
quantifying reverse transcriptase activity in cell-free
extracts. Reactions contained 1 mCi of 3H-TTP (1 Ci/mL,
NEN) and poly rA and oligo dT at concentrations of 0.5
mg/mL and 1.7 Units/mL, respectively, from a stock solu-
tion which was kept at -20°C. For each reaction, 1 μL of
TTP, 4 μL of dH2O, 2.5 μL of rAdT and 2.5 μL of reaction
buffer were mixed. Ten microliters of this reaction mixture
were placed in a round bottom microtiter plate and 15 μL
of virus containing supernatant were added and mixed.
The plate was incubated at 37°C in a humidified incuba-
tor and incubated for 90 min. Following reaction, 10 μL
of the reaction volume were spotted onto a DEAE filter,
washed 5 times for 5 min each in a 5% sodium phosphate
buffer, 2 times for 1 min each in distilled water, 2 times
for 1 min each in 70% ethanol, and then air dried. The
dried filter was subjected to scintillation counting in Opti-
Fluor O.
Pseudotyped HIV production for infectivity assays and
viral particle production were carried out by OyaGen, Inc.
HEK293T cells passaged into 6-well plates were co-trans-
fected 0.5 μg pDHIV3-GFP and 0.5 μg VSV-G, courtesy of
Dr. Baek Kim (Department of Microbiology, University of
Rochester, NY), and 1.0 μg A3G expressing plasmid cour-
tesy of Dr. Harold Smith's laboratory using FuGENE 6
Transfection Reagent (Roche, Indianapolis, IN). The cells
were dosed 4 h and 8 h after transfection with Peptide 2
to bring a final concentration of 50 μM, assuming that all
of the peptide was consumed at the time of the each dos-
ing. 24 h after transfection, the media was replaced with
fresh media containing 50 μM Peptide 2. 24 and 48 h after
transfection, the media was passed through a 0.45 micron
SFCA syringe filter and analyzed for viral particle density
via p24 ELISA (Zeptometrix) and read in a Wallac 1420
plate reader (Perkin Elmer, Watham, MA). The data for
infectivity were evaluated by a two tailed probability anal-
ysis.
Fluorescence Activated Cell Sorting
Cultures of HEK 293T cells at 50% confluency were dosed
with buffer or Peptide-2 as described above and fixed in
70% ethanol (4°C) for 12 h. Cells were resuspended to
0.3 × 103 cells/ml in PBS and RNA digested with 1 mg/ml
RNase A (Sigma) at 37°C for 30 min. Cells were brought
to 20 ug/ml propidium iodide and filtered through 37 umRetrovirology 2007, 4:81 http://www.retrovirology.com/content/4/1/81
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mesh. Fluorescence activated cell sorting was performed
by the University of Rochester Cell Sorting core facility as
a fee for service.
Western Blotting Viral Particles for A3G
Fifteen ng p24-equivalent viral particles were pelleted
through 2 mL 20% sucrose solution in PBS at 148,000 × g
for 2 h. The supernatant was drawn off and the viral parti-
cles were resuspended in 50 μL lysing buffer composed of
1× Reporter Lysis Buffer (Promega) and 1 pellet/10 mL
lysing solution containing Complete® EDTA-free protease
inhibitor (Roche). The viral particle lysates were processed
three times by freezing to -20°C, thawing in a 37°C water
bath and vortexing for 10 seconds. The lysates were ace-
tone precipitated and re-pelleted at 15,000 × g before aspi-
rating and resuspending in SDS PAGE sample buffer. The
lysates were resolved via 10.5% SDS-PAGE and transferred
to BioTrace®NT nitrocellulose membrane (Pall, West
Chester, PA) and probed for A3G with rabbit anti-A3G
primary antibody #10084, (NIH AIDS Research and Ref-
erence Resource Program), and goat anti-rabbit peroxi-
dase conjugated secondary antibody (Invitrogen,
Carlsbad, CA). To verify the p24 normalization deter-
mined in the ELISA, the membranes were probed with
mouse anti-p24 primary antibody #3537 (NIH AIDS
Research and Reference Resource Program) and goat anti-
mouse peroxidase conjugated secondary antibody (Kirke-
gaard & Perry Laboratories, Gaithersburg, MD). Following
the secondary antibodies, the membranes are incubated
with Western Lightning Chemiluminescence Reagent Plus
(Perkin Elmer) and recorded on X-OMAT film (Kodak,
Rochester, NY). The resultant bands were quantified using
NIH ImageJ 1.36b software.
Viral Particle Infectivity Assay
JC53-bl cells (NIH AIDS Research and Reference Resource
Program) were passaged by OyaGen, Inc into 96-well
plates at 10,000 cells/well, 75 μL volumes. The viral parti-
cles were diluted to 6000 pg p24/mL and added to tripli-
cate wells, 25 μg volumes, to the cells when they appeared
40–50% confluent. 48 h after infection, 100 μL of Steady
Glo Reagent (Promega, Madison. WI) was added to each
well and allowed to incubate for 7 minutes at room tem-
perature before reading the luminescence in a Wallac
1420 Multilabel Counter (Perkin Elmer).
Fluorescence microscopy
OyaGen, Inc treated MT2 and H9 cells in culture with 50
μM of Peptide 2-FITC (Sigma, MO) for varying durations
and then centrifuged onto glass slides. The cells were fixed
with 2% paraformaldehyde in PBS for 5 min at 4 oC and
permeabilized with 0.4% Triton X 100 (Sigma) for 5 min
at 4 oC and washed extensively in PBS. Cells were
mounted in DAPI-containing media (Vectasheild, Vector
Labs, Burlingame, CA) and viewed by with an Olympus
BH-2 fluorescence microscope (Orangeburg, NY) and
photographed through with an 8.0 megapixel Olympus
SP-350 camera equipped with an eyepiece telescope.
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